Videregen Company
Bringing tissue repair to life Videregen is a leader in the development of personalised, regenerative products to replace, repair and restore organs and tissues. We are a clinical-stage regenerative medicine company using our proprietary technology platform to develop a range of personalised regenerative products treating chronic, life-threatening orphan indications. Videregen’s programmes are focused on the
Founded Date:
2011
Last Funding Type:
Series A
Headquarters:
Liverpool, Liverpool, United Kingdom
Investors Number:
4
Technology:
Regenerative Medicine
Employee Number:
11-50
Industry:
Risk Mitigation
Estimated Revenue:
$10M to $50M
Number Of Exists:
Series A
Funding Status:
Early Stage Venture
Investor Type:
Company
Investment Stage:
N/A
Total Funding:
$4.27